Autore: M. Patricia Rivera

Dr. Mac Rosty is an Assistant Professor of Medicine in the division of Pulmonary Diseases and Critical Care Medicine at the University of North Carolina at Chapel Hill and is the Associate Director of the Interventional Pulmonology Fellowship Program. She is a practicing interventional pulmonologist and sees patients within the Multidisciplinary Thoracic Oncology Program (MTOP) at UNC. She is involved in leadership roles with the American Thoracic Society, the American College of Chest Physicians as well as within UNC. Dr. Mac Rosty is director of UNC”s clinical pleural disease service and the bronchoscopic lung volume reduction program. Her research focuses on clinical outcomes in malignant pleural disease and translational and clinical research in interventional therapies for obstructive lung diseases. She is also involved with procedural education and designing curricula for trainees in Interventional Pulmonology and Pulmonary and Critical Care Medicine.   Dr. Rivera is a Professor of Medicine and Chief of the division of Pulmonary and Critical Care Medicine at the University of Rochester in Rochester, New York. Before transitioning to URMC, she was at the University of North Carolina (UNC) in Chapel Hill. She was instrumental in developing the UNC Multidisciplinary Thoracic Oncology Program (MTOP) and the Multidisciplinary Lung Cancer Screening Program, and co-developed the North Carolina Lung Cancer Screening Registry. Through NIH/NCI funding, she collaborates with colleagues at UNC to study lung cancer screening implementation and the impact of comorbidities on lung cancer screening outcomes. Other research interests include genetic risk assessment, disparities in lung cancer care, immune-checkpoint inhibitor-related pneumonitis, appropriate staging, and molecular biomarker testing in advanced lung cancer. Dr. Rivera holds multiple leadership roles at professional societies, including President of the American Thoracic Society (2023-2024) and Chair and co-Chair of several Task Forces in the American Cancer Society National Lung Cancer Round Table (NLCRT).